deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02779855

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Sponsor: Amgen

Conditions Breast Cancer Ductal Carcinoma Invasive Breast Carcinoma Invasive Ductal Breast Carcinoma
Interventions Paclitaxel Talimogene laherparepvec
Updated 33 times since 2017 Last updated: Feb 26, 2026 Started: May 2, 2017 Primary completion: Sep 20, 2020 Completion: Aug 26, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Cancer and Ductal Carcinoma, this trial is completed. The trial is conducted by Amgen and has accumulated 33 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Dec 2020 · 6 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~May 2023 · 5 months · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Jun 2025 · 3 months · monthly snapshot~Jun 2025 – ~Oct 2025 · 4 months · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Mar 2026 · 59 days · monthly snapshot~Mar 2026 – present · 6 months · monthly snapshot

Change History

33 versions recorded

  1. Mar 2026 — Present [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Oct 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jun 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Mar 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

▶ Show 28 earlier versions

  1. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  6. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  7. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. May 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Dec 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Jul 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Feb 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  13. Nov 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  14. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  15. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  16. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  17. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  18. Jun 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  19. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  20. Oct 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  21. May 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Suspended → Recruiting

  22. Feb 2019 — May 2019 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  23. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  24. Jul 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  25. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  26. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  27. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  28. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
  • H. Lee Moffitt Cancer Center and Research Institute
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations